In the first five days following the ACC panel in late March, Vytorin and Zetia new prescription market share declined a respective 135 basis points and 74 basis points compared to 175 drop in new prescriptions Vytorin and 156 for Zetia in the first five days following January 14, when the data were disclosed. Furthermore, in the last round, the majority of market share losses occurred in the first week. More thought leaders have stepped forward in support of Vytorin and Zetia.
Pages to are hidden for
"WALL STREET CHOICE: VYTORIN/ZETIA DAMAGE IS NOT AS BAD AS FEARED"Please download to view full document